Non Invasive Imaging Methods for Detecting Primary Aldosteronism: a Clinical Positron EmissionTomography (PET) Study of 18F-Pentixather

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Primary aldosteronism (PA) is the most common endocrine cause of hypertension. 68Ga-pentixafor PET/CT possesses a relatively high sensitivity and specificity for Aldosterone producing adenoma (APA) detection. However, 68Ga is usually eluted from a 68Ge-68Ga generator, only a small amount of isotopes can be achieved once time. \[18F\]AlF-chelation is a promising strategy that would solve these issues. 18F labeled Pentixafor-Based Imaging Agent(\[18F\]AlF-NOTA-Pentixather) has been reported by Andreas Poschenrieder. \[18F\]AlF-NOTA-Pentixather displayed high and CXCR4-specific in vivo uptake in Daudi xenografts (13.9%±0.8% injected dose per gram \[ID/g\] at 1 hour post injection\[p.i.\]). But to date 18F-Pentixather has not been studied in humans. In this program the investigators will estimate the radiation dosimetry of \[18F\]AlF-NOTA-Pentixather, evaluate the sensitivity and specificity of the \[18F\]AlF-NOTA-Pentixather as a probe for APA.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients diagnosed with primary aldosteronism and willing to undergo surgery

• Clinically highly suspected of primary aldosteronism, but the diagnostic test cannot clearly identify the patients

• Postoperative recurrence in patients with primary aldosteronism

Locations
Other Locations
China
First Affiliated Hospital of Dalian Medical University
RECRUITING
Dalian
Contact Information
Primary
Fangfang Sun, MD
sf.f@163.com
18098876916
Backup
Wei Song, PHD
songwei8124@163.com
18098875773
Time Frame
Start Date: 2024-06-12
Estimated Completion Date: 2026-06-30
Participants
Target number of participants: 20
Treatments
Experimental: hyperaldosteronism
Intravenous inject 18F-Pentixather,perform PET/CT imaging at the designated time
Related Therapeutic Areas
Sponsors
Leads: Fangfang Sun

This content was sourced from clinicaltrials.gov

Similar Clinical Trials